A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Trial, in Parallel Groups, to Compare the Safety and Efficacy of Intravitreous Injections of 0.3 mg Pegaptanib Sodium (Macugen), Given as Often as Every 6 Weeks for 2 Years, to Sham Injections in Subjects With Diabetic Macular Edema (DME) Involving the Center of the Macula With An Open-Label Macugen Year 3 Extension.

Trial Profile

A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Trial, in Parallel Groups, to Compare the Safety and Efficacy of Intravitreous Injections of 0.3 mg Pegaptanib Sodium (Macugen), Given as Often as Every 6 Weeks for 2 Years, to Sham Injections in Subjects With Diabetic Macular Edema (DME) Involving the Center of the Macula With An Open-Label Macugen Year 3 Extension.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 26 Sep 2013

At a glance

  • Drugs Pegaptanib (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Most Recent Events

    • 12 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT00605280).
    • 12 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT00605280).
    • 12 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT00605280).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top